Who makes COVIGENIX VAX- 002?

COVIGENIX VAX- 002 is developed by Entos Pharmaceuticals Inc..

What development phase is COVIGENIX VAX- 002 in?

COVIGENIX VAX- 002 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

COVIGENIX VAX- 002

Entos Pharmaceuticals Inc. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	COVIGENIX VAX- 002
Sponsor	Entos Pharmaceuticals Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

COVIGENIX VAX- 002 CI brief — competitive landscape report
COVIGENIX VAX- 002 updates RSS · CI watch RSS
Entos Pharmaceuticals Inc. portfolio CI